Viral Suppression and Its Associated Factors in HIV Patients on Highly Active Antiretroviral Therapy (HAART): A Retrospective Study in the Ho Municipality, Ghana
Table 2
Chi-square test analysis of factors associated with viral suppression among HIV patients at the ART Clinic.
Variable
No viral suppression
Viral suppression
value
Treatment outcome
Suppression rate
89 (31)
195 (69)
Gender
Male
22 (41.51)
31 (58.49)
0.0999
Female
67 (29.00)
164 (71.00)
Age category (years)
<40
34 (36.34)
60 (63.83)
40–49
34 (34.34)
65 (65.66)
0.1152
≥50
21 (23.08)
70 (76.92)
Marital status
Single
43 (31.85)
92 (68.15)
Married
37 (29.37)
89 (70.63)
0.6397
Cohabiting
9 (39.13)
14 (60.87)
Educational status
None
3 (21.43)
11 (78.57)
Basic
49 (31.61)
106 (68.39)
Secondary
33 (32.35)
69 (67.65)
0.8743
Tertiary
4 (30.77)
9 (69.23)
Occupation
None
7 (33.33)
14 (66.67)
Formal
2 (22.22)
7 (77.78)
0.7970
Informal
79 (31.85)
169 (68.15)
Retired
1 (16.67)
5 (83.33)
Clinic attendance
Regular
32 (14.10)
195 (85.90)
<0.0001
Not regular
57 (100.00)
0 (0.00)
Treatment duration
≤3 years
55 (37.16)
93 (62.84)
0.0300
>3 years
34 (25.00)
102 (75.00)
Current HAART regimen
EFV-based regimen
68 (42.24)
165 (57.76)
0.0987
NVP-based regimen
21 (17.07)
30 (82.93)
Data are presented as figures and percentages in parentheses; value is significant at <0.05. EFV-based regimen = AZT/3TC/EFV and TDF/3TC/EFV, NVP-based regimen = TDF/3TC/NVP, D4T/3TC/NVP and AZT/3TC/NVP 3TC = lamivudine, AZT = zidovudine, EFV = efavirenz, NVP = nevirapine, D4T = stavudine, and TDF = tenofovir.
